• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Medtronic (MDT) After FDA Progress And Recalls Is The Undervalued Story Still Intact

    Simply Wall St·11/14/2026 23:15:02
    Listen to the news

    Medtronic (MDT) has been busy on the product front, with fresh FDA backed progress on its neurovascular and hypertension devices arriving alongside voluntary Class II recalls that kept regulatory risk squarely in investor focus.

    Medtronic’s recent mix of FDA clearances, hypertension data and targeted Class II recalls has played out against a share price that closed at US$102.86. The company recorded a 30-day share price return of 9.16% and a 90-day gain of 12.70%, while the 1-year total shareholder return of 10.85% and 3-year total shareholder return of 51.79% point to momentum that has been building over a longer horizon, even as investors reassess both growth potential and regulatory risk.

    Compare Medtronic’s recent mix of product wins and recalls with other device makers that show similar risk reward profiles by scanning the 31 resilient stocks with low risk scores that screens for resilient balance sheets and fundamentals.

    Medtronic’s mix of fresh hypertension data, new neurovascular tools and active recalls now meets a stock trading just below some fair value estimates. Is that modest discount a cushion or a warning that caution still rules?

    Most Popular Narrative: 10.9% Undervalued

    On Simply Wall St, the most followed narrative pegs Medtronic’s fair value at $115.38 against a last close of $102.86. According to LunaRodas, an investor in the Simply Wall St Community who wrote the narrative, that gap comes down to whether recent execution can really support a higher ceiling.

    Medtronic's fiscal first quarter of 2027 arrived with 13.7% organic growth, a number that would be arresting in any quarter. This figure was inflated by an extra selling week that management estimates contributed roughly 670 basis points. Stripping out the calendar effect, the underlying figure still represents, by their own account, the strongest performance in nearly eight years.

    See why 14 investors see Medtronic as 11% undervalued.

    Result: Fair Value of $115.38 (UNDERVALUED)

    Still, Medtronic’s story leans heavily on continued execution in cardiac ablation and CRM, while ongoing recalls and any shift in regulatory tone could undercut that fair value case.

    Find out about the key risks to this Medtronic narrative.

    Next Steps

    Seen enough bullish and cautious signals to have mixed feelings on Medtronic? Act quickly, review the numbers yourself, and weigh the 5 key rewards.

    Looking for more investment ideas beyond Medtronic?

    If Medtronic has sharpened your focus on quality, do not stop there. Broaden your watchlist now, or you risk missing other compelling setups across the market.